May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
What We're Reading: CMS Wants to Penalize Doctors for Prostate Tests
Joy Larsen Haidle on How the Genetic Testing Landscape Has Changed